Pulmonx Co. (NASDAQ:LUNG) Director Sells $130,400.00 in Stock

Pulmonx Co. (NASDAQ:LUNG) Director Glendon E. French III sold 20,000 shares of Pulmonx stock in a transaction that occurred on Thursday, October 17th. The stock was sold at an average price of $6.52, for a total value of $130,400.00. Following the transaction, the director now owns 1,091,974 shares of the company’s stock, valued at $7,119,670.48. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Pulmonx Stock Performance

NASDAQ LUNG opened at $6.13 on Thursday. The firm has a 50-day moving average price of $7.31 and a two-hundred day moving average price of $7.34. Pulmonx Co. has a 12-month low of $5.46 and a 12-month high of $14.84. The company has a market capitalization of $237.94 million, a P/E ratio of -3.98 and a beta of 0.64. The company has a quick ratio of 7.92, a current ratio of 8.97 and a debt-to-equity ratio of 0.37.

Pulmonx (NASDAQ:LUNG) last released its quarterly earnings results on Wednesday, July 31st. The company reported ($0.39) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.02. The company had revenue of $20.78 million during the quarter, compared to the consensus estimate of $20.23 million. Pulmonx had a negative net margin of 75.56% and a negative return on equity of 50.79%. Analysts anticipate that Pulmonx Co. will post -1.64 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of LUNG. nVerses Capital LLC bought a new stake in Pulmonx during the third quarter worth about $26,000. SG Americas Securities LLC bought a new stake in shares of Pulmonx during the 3rd quarter worth approximately $102,000. Cubist Systematic Strategies LLC lifted its holdings in shares of Pulmonx by 141.6% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 109,105 shares of the company’s stock worth $692,000 after acquiring an additional 63,945 shares during the period. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Pulmonx during the 2nd quarter worth approximately $37,000. Finally, Susquehanna Fundamental Investments LLC bought a new position in Pulmonx in the second quarter valued at approximately $477,000. Institutional investors own 91.04% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have commented on LUNG shares. Canaccord Genuity Group lifted their price objective on shares of Pulmonx from $15.00 to $16.00 and gave the stock a “buy” rating in a research report on Thursday, August 1st. Wells Fargo & Company cut their price objective on shares of Pulmonx from $14.00 to $10.00 and set an “equal weight” rating for the company in a research report on Thursday, August 1st. One research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $14.83.

About Pulmonx

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.